Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metformin, diet and breast cancer: an avenue for chemoprevention.

Literature DB >> 19571669

Metformin, diet and breast cancer: an avenue for chemoprevention.

Paola Muti, Franco Berrino, Vittorio Krogh, Anna Villarini, Maddalena Barba, Sabrina Strano, Giovanni Blandino.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2009 PMID： 19571669 DOI： 10.4161/cc.8.16.9226

Source DB: PubMed Journal: Cell Cycle ISSN： 1551-4005 Impact factor: 4.534

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

Authors: Giovanni Blandino; Mariacristina Valerio; Mario Cioce; Federica Mori; Luca Casadei; Claudio Pulito; Andrea Sacconi; Francesca Biagioni; Giancarlo Cortese; Sergio Galanti; Cesare Manetti; Gennaro Citro; Paola Muti; Sabrina Strano
Journal: Nat Commun Date: 2012-05-29 Impact factor: 14.919

Review 2. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

Authors: R J Stevens; R Ali; C R Bankhead; M A Bethel; B J Cairns; R P Camisasca; F L Crowe; A J Farmer; S Harrison; J A Hirst; P Home; S E Kahn; J H McLellan; R Perera; A Plüddemann; A Ramachandran; N W Roberts; P W Rose; A Schweizer; G Viberti; R R Holman
Journal: Diabetologia Date: 2012-08-10 Impact factor: 10.122

3. Diabetes, metformin, and breast cancer in postmenopausal women.

Authors: Rowan T Chlebowski; Anne McTiernan; Jean Wactawski-Wende; JoAnn E Manson; Aaron K Aragaki; Thomas Rohan; Eli Ipp; Virginia G Kaklamani; Mara Vitolins; Robert Wallace; Marc Gunter; Lawrence S Phillips; Howard Strickler; Karen Margolis; David M Euhus
Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544

4. Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis.

Authors: Zhaodi Zheng; Yan Bian; Yang Zhang; Guanghui Ren; Guorong Li
Journal: Cell Cycle Date: 2020-04-14 Impact factor: 4.534

5. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors: Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal: Sci Transl Med Date: 2018-03-14 Impact factor: 17.956

Metformin, diet and breast cancer: an avenue for chemoprevention.

1. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

Review 2. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

3. Diabetes, metformin, and breast cancer in postmenopausal women.

4. Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis.

5. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

6. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin.

7. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.

Review 8. Metformin for aging and cancer prevention.

9. Hormesis does not make sense except in the light of TOR-driven aging.

10. Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk.